# Abogenbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abogenbio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.abogenbio.com
- Total disclosed funding: $1.1B
- Latest round: Series C (Nov 29, 2021)
- Investors on record: 40

## About

Established in 2019 and based in Suzhou, China, Abogenbio operates as a nucleic acid drug developer that provides drug treatment services. The company has a branch and office in Shanghai and Beijing. In June 2020, the novel coronavirus mRNA vaccine (ARCoV) jointly developed by Abogenbio, the Institute of Military Medicine of the Academy of Military Sciences and Yunnan Watson Biotechnology, officially passed the drug clinical trial approval of the National Medical Products Administration. In November 2021, Abogenbio raised USD 300 million in series C+ funding co-led by new investor SB Investment Advisers and returning investor 5Y Capital.


The company uses mRNA technology and LNP platform to develop infectious disease control, tumor immunization, tumor vaccines and protein replacement therapy. Its pipeline product includes ARCoV.

## Funding rounds

- Series C, Nov 29, 2021, $300M — 5Y Capital, Oriental Fortune Capital, SB Investment Advisers, New Frontier, Jinyi Capital, IMO Ventures, Chimera Capital, Zhejiang Future Assets Mangement Company.ltd, DNE Capital
- Series C, Aug 19, 2021, $700M — Invesco, Temasek Holdings, Legend Capital, Qiming Venture Partners, Lilly Asia Ventures, 5Y Capital, YF Capital, Boyu Capital, MSA Capital, Kaiser Permanente Ventures, PICC Capital Equity Investment, Gaorong Ventures, HighLight Capital, Loyal Valley Capital, Yingke Private Equity, Everbright ReinFore, Alwin Capital, Tsing Song Capital, BioTrack Capital, Winfast Holding, Firstlight Capital, AIHC Capital, GL Ventures, Youshan Capital, Octagon Capital Advisors, Tiger Jade Capital, Oriental Spring
- Series B, Apr 8, 2021, $92M — YF Capital, PICC Capital Equity Investment, HighLight Capital, TF Capital, LYFE Capital, SDIC Venture Capital, Ming Bioventures, GL Ventures
- Series A, Nov 6, 2020, $23M — SDIC Venture Capital, GL Ventures, Chengdu Kanghua Biological Products Co.,Ltd.
- Angel, Jan 27, 2019 — TF Capital

## Investors

- TF Capital — Angel, Series B
- SDIC Venture Capital (https://capitalatlas.ai/funds/sdic-venture-capital) — Series A, Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series A, Series B, Series C
- Chengdu Kanghua Biological Products Co.,Ltd. — Series A
- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series B, Series C
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series B, Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series B, Series C
- LYFE Capital — Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series B
- Invesco (https://capitalatlas.ai/funds/invesco) — Series C
- Temasek Holdings — Series C
- Legend Capital — Series C
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series C
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C
- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series C
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series C
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series C
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series C
- Yingke Private Equity (https://capitalatlas.ai/funds/yingke-private-equity) — Series C
- Everbright ReinFore (https://capitalatlas.ai/funds/everbright-reinfore) — Series C
- Alwin Capital — Series C
- Tsing Song Capital (https://capitalatlas.ai/funds/tsing-song-capital) — Series C
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series C
- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series C
- Firstlight Capital — Series C
- AIHC Capital — Series C
- Youshan Capital (https://capitalatlas.ai/funds/youshan-capital) — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C
- Tiger Jade Capital (https://capitalatlas.ai/funds/tiger-jade-capital) — Series C
- Oriental Spring — Series C
- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C
- New Frontier (https://capitalatlas.ai/funds/new-frontier) — Series C
- Jinyi Capital (https://capitalatlas.ai/funds/jinyi-capital) — Series C
- IMO Ventures (https://capitalatlas.ai/funds/imo-ventures) — Series C
- Chimera Capital (https://capitalatlas.ai/funds/chimera-capital) — Series C
- Zhejiang Future Assets Mangement Company.ltd — Series C
- DNE Capital (https://capitalatlas.ai/funds/dne-capital) — Series C